Hodgkin Lymphoma (HL) market | Size, Share, Growth

Hodgkin Lymphoma (HL) market Research Report-Size, Share, Growth, and Trend Analysis | Forecast (2022 - 2032)

Published: 2025 - January

Report Code: VMR-17628

Region: Global

Request Sample

Customization

Ask an Expert

Enquire Enquire Before Buying

The Hodgkin Lymphoma (HL) market focuses on the diagnosis, treatment, and management of a type of lymphatic cancer originating in the lymph nodes, characterized by the presence of Reed-Sternberg cells. This market is evolving rapidly, driven by innovative immunotherapies, targeted therapies, and advancements in biologics, which aim to improve patient survival rates and reduce side effects. The segmentation encompasses classical Hodgkin Lymphoma (cHL) and Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL), with therapies tailored for relapsed/refractory and frontline treatment settings.

Disruptive Impact and Opportunities:

Emerging immunotherapies like Camidanlumab Tesirine and autologous CD30-targeted therapies present cutting-edge advancements. Enhanced treatment regimens with improved efficacy and simplified administration methods for improved patient compliance. A focus on reducing toxicities associated with traditional chemotherapy by incorporating immune checkpoint inhibitors like Tislelizumab. The growing prevalence of HL globally, particularly among young adults, creates a substantial market for novel therapies.

Emerging Drugs:

AFM-13
Camidanlumab Tesirine (ADCT-301)
Tislelizumab (BGB-A317)
Autologous CD30

Marketed Drugs:

Brentuximab Vedotin (Adcetris)
Rituximab (Rituxan)
Nivolumab (Opdivo)
Pembrolizumab (Keytruda)

Key Companies:

Affimed Therapeutics
ADC Therapeutics
BeiGene
CStone Pharmaceuticals
4SC Therapeutics
Tessa Therapeutics

Market Segmentation:

By Type

Classical Hodgkin Lymphoma (cHL)
- Nodular Sclerosis
- Mixed Cellularity
- Lymphocyte-Rich
- Lymphocyte-Depleted
Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)

By Administration Type

· Oral

· Injectable

Intravenous (IV)
Subcutaneous (SC)

What’s in It for You?

Uncover growth opportunities in the HL market driven by emerging immunotherapies.
Evaluate competitive dynamics and key players shaping the landscape.

Access insights into evolving treatment paradigms and patient-centric solutions.

Leverage actionable data for strategic planning, investment, and market entry.

Hodgkin Lymphoma Market Analysis (Market Size & CAGR, Epidemiology, Marketed Therapies, Emerging Drugs, Clinical Trials, Key Approvals & Anticipated Loss of Exclusivity, Opportunities, Unmet Needs, Company Profiles)

1. Hodgkin Lymphoma Market - Executive Summary

1.1. Introduction

1.2. Objectives

1.3. Key Findings

1.3.1. Market Size 2022 & 2032: By Key Country (10MM)

1.3.2. Global Market Size 2022 & 2032: By Key Segment

1.3.3. Key Investments & Startup Analysis

1.4. Research Methodology

2. Understanding the Disease

2.1. Disease Overview

2.2. Classification

2.3. Signs and Symptoms

2.4. Risk Factors

2.5. Causes

2.6. Disease Biology & Digital Innovations

2.7. Stages & Staging System

2.8. Diagnostic Algorithm

2.9. Current Treatment Practices & Algorithm

2.10. Current Standard of Care and Treatment Gaps

2.11. Patient Demographics and Treatment Pathways

3. Guidelines

4. Unmet Needs

5. Epidemiology and Patient Population

5.1. Epidemiology Key Findings

5.2. Assumptions and Rationale: 10MM

5.3. Epidemiology Scenario: 10MM

5.4. U.S. Epidemiology Scenario

5.5. EU-5 Epidemiology

5.5.1. U.K. Epidemiology Scenario

5.5.2. Germany Epidemiology Scenario

5.5.3. France Epidemiology Scenario

5.5.4. Italy Epidemiology Scenario

5.5.5. Spain Epidemiology Scenario

5.6. Japan Epidemiology Scenario

5.7. China Epidemiology Scenario

5.8. Australia Epidemiology Scenario

5.9. India Epidemiology Scenario

6. Real-world Data & Real-world Evidence

7. Drug Development Landscape

7.1. Existing Key Drug Candidate Profiles/ Marketed Therapies

7.1.1. Brentuximab vedotin (Adcetris)

7.1.1.1. Product Description

7.1.1.2. Regulatory Milestones

7.1.1.3. Other Developmental Activities

7.1.1.4. Pivotal Clinical Trials

7.1.1.5. Ongoing Current Pipeline Activity

7.1.2. Rituximab (Rituxan)

7.1.2.1. Product Description

7.1.2.2. Regulatory Milestones

7.1.2.3. Other Developmental Activities

7.1.2.4. Pivotal Clinical Trials

7.1.2.5. Ongoing Current Pipeline Activity

7.1.3. Nivolumab (Opdivo)

7.1.3.1. Product Description

7.1.3.2. Regulatory Milestones

7.1.3.3. Other Developmental Activities

7.1.3.4. Pivotal Clinical Trials

7.1.3.5. Ongoing Current Pipeline Activity

7.1.4. Pembrolizumab (Keytruda)

7.1.4.1. Product Description

7.1.4.2. Regulatory Milestones

7.1.4.3. Other Developmental Activities

7.1.4.4. Pivotal Clinical Trials

7.1.4.5. Ongoing Current Pipeline Activity

7.2. Competitive Analysis and Differentiation

7.3. Overview of Similar/Competing Drugs in Clinical Trials

7.4. Future Trends and Emerging Drugs

7.4.1. AFM-13

7.4.1.1. Product Description

7.4.1.2. Clinical Development

7.4.1.3. Safety and Efficacy

7.4.2. Camidanlumab Tesirine (ADCT-301)

7.4.2.1. Product Description

7.4.2.2. Clinical Development

7.4.2.3. Safety and Efficacy

7.4.3. Tislelizumab (BGB-A317)

7.4.3.1. Product Description

7.4.3.2. Clinical Development

7.4.3.3. Safety and Efficacy

7.4.4. Autologous CD30

7.4.4.1. Product Description

7.4.4.2. Clinical Development

7.4.4.3. Safety and Efficacy

8. Regulatory Strategy and Potential Challenges

8.1. Regulatory Pathways in Key Markets

8.2. Anticipated Regulatory Hurdles and Mitigation Strategies

8.3. Case Studies in Oncology Drug Regulation

8.4. Impact of Potential Changes to Regulatory Framework

9. Commercial Landscape

9.1. Market Size & Growth Rates

9.2. Key Approvals & Anticipated Loss of Exclusivity

9.3. PESTLE & Porter’s Five Forces Analysis

9.4. Market Shares, Positioning/Ranking

9.5. Market Drivers

9.6. Identification of Threats

9.7. Digital Evolution in Commercialization

10. Market Segmentation

10.1. Market by Type

10.1.1. Classic Hodgkin Lymphoma

10.1.2. Nodular Lymphocyte-Predominant Hodgkin Lymphoma

10.2. Market by Therapy Type

10.2.1. Medication

10.2.2. Chemotherapy

10.2.3. Surgery

11. Pricing, Reimbursement, and Access

11.1. Competitive Pricing Analysis

11.2. Reimbursement Landscape and Challenges

11.3. Strategies for Market Access and Equity

11.4. Patient Spending/Expenditure Analysis

12. Future Trends, Disruptions, and Opportunities

12.1. Analysis of Emerging Trends

12.2. Technological Impact

12.3. Impact of Potential Market Disruptors

12.4. Opportunities for Future Development and Expansion

12.5. Considerations for Investment Opportunities

13. Global Market Dynamics

13.1. Regional Regulatory Disparities

13.2. Cross-Border Partnership Strategies

13.3. Global Supply Chain Dynamics

13.4. Case Studies: Success and Failure in Global Markets

13.5. Strategies for Global Expansion and Localization

14. Company Profiles

14.1. Affimed Therapeutics

14.2. ACD Therapeutics

14.3. BeiGene

14.4. Cstone Pharmaceuticals

14.5. 4SC Therapeutics

14.6. Tessa Ther

14.7. F. Hoffman-La Roche Ltd.

14.8. Johnson & Johnson

14.9. Bayer AG

14.10. Eli Lilly and Company

Download Sample

Full Name *

Job Title *

Company *

Email *

Phone *

Country *

Message

↻

The field with (*) is required.

Choose License Type

Excel Data Pack

2500

Single User

4250

Multi User

5250

Corporate User

6900